Peter Guzzo Joins Variational AI as Vice President, Head of Drug Discovery
Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecule therapeutics, today announced that Peter Guzzo, Ph.D., has joined the company as vice president, head of drug discovery.
Variational AI Partners with the University of British Columbia and adMare BioInnovations to Develop COVID-19 Therapeutic
Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecule therapeutics, today announced the company has generated and ordered compounds for validation in partnership with the University of British Columbia (UBC) and adMare BioInnovations to develop a novel SARS-CoV-2 Main Protease (3CLpro) inhibitor.
Variational AI Secures $US3.5 Million in Seed Funding to Apply State-of-the-Art AI Platform to Generate Novel Small Molecule Therapeutics for Drug Development
Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecules, today announced that it has raised $US3.5 million ($CDN4.3 million) in seed funding.
